BRIEF-GSK says early dolutegravir trial data encouraging

LONDON, March 7 Thu Mar 7, 2013 2:08am EST

LONDON, March 7 (Reuters) - GlaxoSmithKline Plc : * Dolutegravir sailing study in hiv announced * At 24 weeks, 79 percent of dolutegravir participants virologically suppressed

versus 70 percent on raltegravir * Says encouraging early data in dolutegravir sailing study

FILED UNDER: